“The present circumstance has exposed some structural weaknesses during the EU’s medicines source chain and a large dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides explained. She advised that offer chain issues be tackled in an EU pharmaceutical approach predicted to become launched by the top f